Effect of Drug Clinical Trial
Official title:
PFA 100 Evaluation and Reference Interval HOACNY
The purpose of this research is to evaluate instrument functionality and develop a reference range of normal data by healthy volunteers.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | January 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18 years or older - Able to consent to study Exclusion Criteria from entire study - Primary hemostasis diagnosis - Von Willebrand Disease - Bernard-Soulier syndrome - Glanzmann thrombasthenia - Idiopathic thrombocytopenic purpura - Drug-induced thrombocytopenia - Heparin-induced thrombocytopenia - Thrombotic thrombocytopenic purpura - Hemolytic uremic syndrome - Participant is on anticoagulant therapy - Specifically thienopyrdines [Ticlopidine, Clopidogrel] and GPIIb/IIIa inhibitors [ReoPro, Aggrastat, Integrilin] - Participant is on medication that contains ASA or aspirin (see list below in Study Procedure) - Participant is on nonsteroidal anti-inflammatory agents that are known to induce temporary platelet dysfunction (see list below in Study Procedure) - Participant is on non-prescription medications containing aspirin (see list below in Study Procedure) - PFA-100 result falls outside of reference interval listed in the package insert (suggested criteria in the PFA-100 Evaluation Protocol as described in the PFA-100 System: Getting Started Guide) - If hematocrit is less than 35% - If platelets are less than 150 x10^3/uL Exclusion Criteria from Cohort B but not Cohort A - Potential for adverse reactions between current medication and aspirin as dictated by staff pharmacist - Allergy to ASA or aspirin - Previous allergic reaction to ASA or aspirin - Participant is pregnant - Asthma, or history of, with nasal polyps and rhinitis - Stomach ulcers or bleeding - Severe kidney disease - Severe liver disease - Hemophilia - Pregnant or breast feeding |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Hematology Oncology Associates of Central New York |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Instrument Evaluation Protocol-PFA100 Instrumentation [platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges] | This portion of the study is to ensure that the functionality of the instrumentation is working properly.
For each participant, their pre-aspirin dose closure times will be compared to their post-aspirin dose closure times. The typical pattern seen in subjects with normal platelet function (pre-aspirin testing) is closure time (CT) results within the reference range for both the COL/EPI and COL/ADP cartridges (normal). In general, the pattern seen after aspirin ingestion is a CT result outside the reference range (abnormal) with COL/EPI and within the reference range for COL/ADP (normal). |
3 months | |
Primary | Reference Interval Protocol-PFA100 Instrumentation [platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges] | For each participant in the non-intervention/placebo arm, platelet function as measured by aperture closure time monitored in seconds for collagen/epinephrine (COL/EPI) cartridges and collagen/ADP (COL/ADP) cartridges will be captured.
Following guidelines as stated per CLSI document EP28-A3c, a reference interval will be developed from this captured data. |
3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04549012 -
Determination of Blood Loss After CS
|
Early Phase 1 | |
Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT04573049 -
The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement
|
Phase 4 | |
Not yet recruiting |
NCT04562493 -
Comparative Effect of Transforaminal Injection of Magnesium Sulphate Versus Ozone Therapy on Oxidative Stress Biomarkers in Lumbar Disc Related Radicular Pain
|
N/A | |
Completed |
NCT04762147 -
Comparison of Perioperative Analgesia Between Intravenous Paracetamol and Fentanyl for Rigid Hysteroscopy
|
Phase 3 | |
Not yet recruiting |
NCT05510986 -
The Effect of Oxycodone Hydrochloride on CRBD After TURBT Under General Anesthesia
|
N/A | |
Completed |
NCT06432309 -
Opicapone as Adjunctive Therapy to Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease
|
N/A | |
Recruiting |
NCT05968885 -
Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity
|
Phase 4 | |
Recruiting |
NCT05092074 -
Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection
|
||
Recruiting |
NCT05595044 -
Effect of Vitamin D Therapy in Autism Spectrum Disorder
|
Phase 1 | |
Completed |
NCT05060913 -
Emla Cream Versus Benzocaine on Analgesia
|
Early Phase 1 | |
Not yet recruiting |
NCT05293119 -
Role of Tofacitinib in Vitiligo Patients
|
Early Phase 1 | |
Not yet recruiting |
NCT06414018 -
Effect of Equivalent Dose Sufentanil and Afentanil in Bronchoscopic Treatment
|
N/A | |
Recruiting |
NCT05786859 -
The Efficacy and Safety of Rifaximin Treatment
|
Early Phase 1 | |
Not yet recruiting |
NCT06290219 -
The Effect of Platelet-rich Plasma Nasal Injection in the Treatment of Traumatic Olfactory Dysfunction
|
Phase 3 | |
Completed |
NCT05277480 -
Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma (OAIE)
|
Phase 2 | |
Recruiting |
NCT05482451 -
Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer
|
Early Phase 1 | |
Not yet recruiting |
NCT04892212 -
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05918146 -
Dextrose Therapy on Physical Therapy in Subdeltoid Bursitis
|
Phase 4 |